angiopoietin

(redirected from Ang2)

angiopoietin

(an″jē-ō-poy-ē′tĭn; -poy′ĕ-tĭn) [ angio- + -poiet(ic) + -in]
Any of several genes (or the proteins they encode) that stimulate new blood vessel formation. The proteins encoded by angiopoietin are found in healthy cardiac endothelium and in diseased tissues such as arthritic joints and malignant tumors.
References in periodicals archive ?
Regeneron (REGN) downgraded to Neutral from Buy at BTIG with analyst Dane Leone stating that he is optimistic that Roche's (RHHBY) coming read-out of the BOULEVARD study may show encouraging clinical results on Feb 13 to support a pivotal effort and may show VEGF + ANG2 inhibition may provide incremental benefits over VEGF therapy alone in DME and potentially wetAMD.
Ang2 and VEGF together therefore have the potential to influence the pathological development of new blood vessels and the permeability of blood vessel walls in certain diseases of the eye.
Six main angiogenic genes (VEGF165, Kdr, Angl, Ang2, Tiel and Tie2) participating in these two signaling pathways were selected to study.
Angl and Ang2 are specific ligands of Tie2 with similar affinity and the activation of Tie2 would promote vessel assembly and maturation.
El factor soluble Ang1 estabiliza el endotelio, mientras que Ang2 aumenta la fuga capilar.
REGN910 is a fully human monoclonal antibody discovered using Regeneron VelocImmune antibody technology that binds and inhibits Ang2.
Thus, Ang2 is one of the earliest tumor markers described; it is also one of the most general because it marks co-opted vessels and not the tumor cells themselves.
Ang2 is one of the most potent vasopressors in humans and plays an important role in blood pressure regulation (2,3).
Inhibition of HPTP restores Tie2 signaling and overcomes the effect of the natural Tie2 inhibitor, Ang2, restoring vascular stability and, in turn, reducing vascular leak and pathologic angiogenesis.
These in vivo data showed silencing of Ang2 in the lung, and contribute to existing data demonstrating the potential for developing RNAi therapeutics that target diseases associated with the lung, such as respiratory syncytial virus (RSV) infection, influenza, and asthma.
Yancopoulos continued, "We have also recently reported on the cloning of another member of the Angiopoietin family, Ang2, which appears to be a negative regulator of angiogenesis.
5,814,464 covering the gene that encodes human Angiopoietin-2 (Ang2) protein and a method of using the gene to make the Ang2 protein.